Insulin Peglispro + Insulin Lispro + Insulin Glargine
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
Jun 1, 2014 โ Dec 1, 2014
NCT ID
NCT02152384About Insulin Peglispro + Insulin Lispro + Insulin Glargine
Insulin Peglispro + Insulin Lispro + Insulin Glargine is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02152384. Target conditions include Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02152384 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1